300573 Stock Overview Engages in the research and development, production, and sale of ophthalmic medications in the People’s Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Shenyang Xingqi Pharmaceutical Co.,Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Shenyang Xingqi PharmaceuticalLtd Historical stock prices Current Share Price CN¥73.22 52 Week High CN¥214.36 52 Week Low CN¥64.88 Beta 0.19 1 Month Change -10.94% 3 Month Change -19.07% 1 Year Change -43.78% 3 Year Change 4.91% 5 Year Change n/a Change since IPO 4.15%
Recent News & Updates
Third quarter 2024 earnings released: EPS: CN¥0.70 (vs CN¥0.54 in 3Q 2023) Oct 30
Investor sentiment deteriorates as stock falls 25% Oct 15
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Sep 30
New major risk - Share price stability Sep 27
Investor sentiment improves as stock rises 17% Sep 26
Investor sentiment deteriorates as stock falls 19% Sep 04 See more updates
Third quarter 2024 earnings released: EPS: CN¥0.70 (vs CN¥0.54 in 3Q 2023) Oct 30
Investor sentiment deteriorates as stock falls 25% Oct 15
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Sep 30
New major risk - Share price stability Sep 27
Investor sentiment improves as stock rises 17% Sep 26
Investor sentiment deteriorates as stock falls 19% Sep 04 Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024 Aug 30
Second quarter 2024 earnings released: EPS: CN¥0.77 (vs CN¥0.39 in 2Q 2023) Aug 29
High number of new directors Aug 02
New minor risk - Share price stability Jul 31
Investor sentiment deteriorates as stock falls 16% Jul 29
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Jun 29
Dividend of CN¥3.00 announced May 17
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024 May 16
First quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.16 in 1Q 2023) Apr 26
Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2024 Apr 20
Full year 2023 earnings released: EPS: CN¥1.93 (vs CN¥1.72 in FY 2022) Apr 18
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Mar 30
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections Jan 09
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024 Dec 29
Third quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.66 in 3Q 2022) Oct 24
New major risk - Share price stability Oct 11
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 24, 2023 Sep 30
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Interim Dividend on A Shares for the Year 2023, Payable on 22 September 2023 Sep 19
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Interim Profit Distribution Plan for 2023 Sep 15
High number of new directors Sep 01
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Dividend for the First Half of 2023 Aug 30
Investor sentiment improves as stock rises 23% Apr 26
Full year 2022 earnings released: EPS: CN¥2.41 (vs CN¥2.39 in FY 2021) Apr 24
Less than half of directors are independent Apr 14
Investor sentiment deteriorates as stock falls 17% Mar 02
Investor sentiment improved over the past week Dec 07
Investor sentiment improved over the past week Nov 03
Now 21% undervalued Nov 01
Third quarter 2022 earnings released: EPS: CN¥0.93 (vs CN¥0.90 in 3Q 2021) Oct 28
Shenyang Xingqi Pharmaceutical Co.,Ltd Announces Interim Dividend on A Shares for the Year 2021, Payable on September 23, 2022 Sep 18
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Interim Cash Dividend for 2022 Sep 15
Shenyang Xingqi Pharmaceutical Announces Profit Distribution Proposal for the First Half of 2022 Aug 30
Second quarter 2022 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in 2Q 2021) Aug 29
Investor sentiment deteriorated over the past week Jul 12
Investor sentiment deteriorated over the past week Jun 27
Investor sentiment improved over the past week Jun 01 Shenyang Xingqi Pharmaceutical Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented on A Shares, Payable on 20 May 2022
Investor sentiment improved over the past week May 03
First quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.40 in 1Q 2021) Apr 27
Shenyang Xingqi Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for the Year 2021 Apr 21
Investor sentiment deteriorated over the past week Jan 25
Investor sentiment deteriorated over the past week Nov 25
Investor sentiment improved over the past week Nov 03
Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.47 in 3Q 2020) Oct 28
Investor sentiment improved over the past week Sep 02
Second quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.32 in 2Q 2020) Aug 28
Investor sentiment deteriorated over the past week Jul 29
Investor sentiment deteriorated over the past week Jul 03
Shenyang Xingqi Pharmaceutical Co., Ltd. Announces Final Cash Dividend for the Year 2020, Payable on 21 May 2021 May 15
Full year 2020 earnings released: EPS CN¥1.09 (vs CN¥0.45 in FY 2019) Apr 20
Shenyang Xingqi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021 Mar 09
New 90-day low: CN¥93.15 Jan 28
Shenyang Xingqi Pharmaceutical Co., Ltd. Approves Directorate Elections Jan 09
New 90-day low: CN¥107 Dec 25
New 90-day low: CN¥124 Nov 18
Third quarter earnings released Oct 29
New 90-day low: CN¥129 Oct 23
New 90-day low - CN¥136 Sep 10
Shenyang Xingqi Pharmaceutical Co.,Ltd announced that it expects to receive CNY 800 million in funding Sep 08
Earnings released Aug 27
Shenyang Xingqi Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 27, 2020 Aug 11 Shareholder Returns 300573 CN Pharmaceuticals CN Market 7D -6.0% -1.9% -0.6% 1Y -43.8% -5.7% 8.3%
See full shareholder returns
Return vs Market: 300573 underperformed the CN Market which returned 9.2% over the past year.
Price Volatility Is 300573's price volatile compared to industry and market? 300573 volatility 300573 Average Weekly Movement 11.5% Pharmaceuticals Industry Average Movement 7.3% Market Average Movement 8.7% 10% most volatile stocks in CN Market 12.9% 10% least volatile stocks in CN Market 5.6%
Stable Share Price: 300573's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300573's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People’s Republic of China. The company offers corneal, anti-bacteria, artificial tears, anti-inflammation, anti-allergic, mydriactics, anti-fatigue, and dry eye treatment products.
Show more Shenyang Xingqi Pharmaceutical Co.,Ltd. Fundamentals Summary How do Shenyang Xingqi PharmaceuticalLtd's earnings and revenue compare to its market cap? 300573 fundamental statistics Market cap CN¥12.83b Earnings (TTM ) CN¥348.47m Revenue (TTM ) CN¥1.80b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 300573 income statement (TTM ) Revenue CN¥1.80b Cost of Revenue CN¥403.79m Gross Profit CN¥1.40b Other Expenses CN¥1.05b Earnings CN¥348.47m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 1.99 Gross Margin 77.59% Net Profit Margin 19.34% Debt/Equity Ratio 14.1%
How did 300573 perform over the long term?
See historical performance and comparison Dividends
2.8% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 12:45 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shenyang Xingqi Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tielin Chen Topsperity Securities Jing Chen Topsperity Securities
Show 0 more analysts 
